ESCO TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ESCO TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jul 2, 2019 | $37.00M | Nov 29, 2019 |
| FY2018 | Sep 30, 2018 | $231.09M | Nov 29, 2018 |
| FY2018 | Jun 30, 2018 | $192.22M | Nov 29, 2018 |
| FY2018 | Mar 31, 2018 | $174.78M | Nov 29, 2018 |
| FY2018 | Mar 14, 2018 | $8.00M | Nov 29, 2018 |
| FY2018 | Dec 31, 2017 | $173.50M | Nov 29, 2018 |
| FY2018 | Sep 30, 2017 | $207.01M | Nov 29, 2018 |
| FY2018 | Aug 30, 2017 | $14.00M | Nov 29, 2018 |
| FY2018 | Jun 30, 2017 | $171.19M | Nov 29, 2018 |
| FY2018 | May 25, 2017 | $25.00M | Nov 29, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.10B | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $919.13M | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | $855.79M | Dec 1, 2025 |
| FY2024 | Sep 30, 2022 | $857.50M | Nov 29, 2024 |
| FY2023 | Sep 30, 2021 | $715.44M | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | $208.03M | Nov 30, 2020 |
| FY2020 | Jun 30, 2020 | $172.67M | Nov 30, 2020 |
| FY2020 | Mar 31, 2020 | $180.49M | Nov 30, 2020 |
| FY2020 | Dec 31, 2019 | $171.73M | Nov 30, 2020 |
| FY2020 | Sep 30, 2019 | $213.18M | Nov 30, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $207.01M | Nov 29, 2017 |
| FY2017 | Jun 30, 2017 | $171.19M | Nov 29, 2017 |
| FY2017 | Mar 31, 2017 | $161.18M | Nov 29, 2017 |
| FY2017 | Dec 31, 2016 | $146.37M | Nov 29, 2017 |
| FY2017 | Sep 30, 2016 | $159.51M | Nov 29, 2017 |
| FY2017 | Jun 30, 2016 | $140.19M | Nov 29, 2017 |
| FY2017 | Mar 31, 2016 | $138.93M | Nov 29, 2017 |
| FY2017 | Dec 31, 2015 | $132.83M | Nov 29, 2017 |
| FY2016 | Sep 30, 2015 | $153.61M | Nov 29, 2016 |
| FY2016 | Jun 30, 2015 | $134.19M | Nov 29, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $299.22M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $101.88M | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | $92.55M | Dec 1, 2025 |
| FY2024 | Sep 30, 2022 | $82.32M | Nov 29, 2024 |
| FY2023 | Sep 30, 2021 | $63.50M | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | ($21.31M) | Nov 30, 2020 |
| FY2020 | Jun 30, 2020 | $18.69M | Nov 30, 2020 |
| FY2020 | Mar 31, 2020 | $17.82M | Nov 30, 2020 |
| FY2020 | Dec 31, 2019 | $86.78M | Nov 30, 2020 |
| FY2020 | Sep 30, 2019 | $24.86M | Nov 30, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $170.36M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $146.20M | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | $119.14M | Dec 1, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $23.00M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $12.00M | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | $13.00M | Dec 1, 2025 |
| FY2024 | Sep 30, 2022 | $12.30M | Nov 29, 2024 |
| FY2023 | Sep 30, 2021 | $15.40M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $13.30M | Nov 29, 2022 |
| FY2021 | Sep 30, 2019 | $12.10M | Nov 29, 2021 |
| FY2020 | Sep 30, 2018 | $10.90M | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $14.00M | Nov 29, 2019 |
| FY2018 | Sep 30, 2016 | $12.20M | Nov 29, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $234.64M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $208.20M | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | $203.46M | Dec 1, 2025 |
| FY2024 | Sep 30, 2022 | $195.13M | Nov 29, 2024 |
| FY2023 | Sep 30, 2021 | $167.53M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $159.49M | Nov 29, 2022 |
| FY2021 | Sep 30, 2019 | $162.73M | Nov 29, 2021 |
| FY2020 | Sep 30, 2018 | $153.07M | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $148.43M | Nov 29, 2019 |
| FY2018 | Sep 30, 2016 | $131.49M | Nov 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $241.94M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $127.54M | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | $76.89M | Dec 1, 2025 |
| FY2024 | Sep 30, 2022 | $135.28M | Nov 29, 2024 |
| FY2023 | Sep 30, 2021 | $123.14M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $82.28M | Nov 29, 2022 |
| FY2021 | Sep 30, 2019 | $105.14M | Nov 29, 2021 |
| FY2020 | Sep 30, 2018 | $93.26M | Nov 30, 2020 |
| FY2019 | Sep 30, 2017 | $67.34M | Nov 29, 2019 |
| FY2018 | Sep 30, 2016 | $73.86M | Nov 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.41B | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $1.84B | Dec 1, 2025 |
| FY2024 | Sep 30, 2023 | $1.68B | Nov 29, 2024 |
| FY2023 | Sep 30, 2022 | $1.65B | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $1.58B | Nov 29, 2022 |
| FY2021 | Sep 30, 2020 | $1.37B | Nov 29, 2021 |
| FY2020 | Sep 30, 2019 | $1.47B | Nov 30, 2020 |
| FY2019 | Sep 30, 2018 | $1.27B | Nov 29, 2019 |
| FY2018 | Sep 30, 2017 | $1.26B | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $978.37M | Nov 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $869.52M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $601.27M | Dec 1, 2025 |
| FY2024 | Sep 30, 2023 | $552.07M | Nov 29, 2024 |
| FY2023 | Sep 30, 2022 | $606.30M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $557.65M | Nov 29, 2022 |
| FY2021 | Sep 30, 2020 | $411.16M | Nov 29, 2021 |
| FY2020 | Sep 30, 2019 | $640.50M | Nov 30, 2020 |
| FY2019 | Sep 30, 2018 | $505.71M | Nov 29, 2019 |
| FY2018 | Sep 30, 2017 | $588.53M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $363.26M | Nov 29, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.54B | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $1.24B | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | $1.13B | Dec 1, 2025 |
| FY2025 | Sep 30, 2022 | $1.05B | Dec 1, 2025 |
| FY2024 | Sep 30, 2021 | $1.02B | Nov 29, 2024 |
| FY2023 | Sep 30, 2020 | $959.03M | Nov 29, 2023 |
| FY2022 | Sep 30, 2019 | $826.22M | Nov 29, 2022 |
| FY2021 | Sep 30, 2018 | $759.41M | Nov 29, 2021 |
| FY2020 | Sep 30, 2017 | $671.92M | Nov 30, 2020 |
| FY2019 | Sep 30, 2016 | $615.11M | Nov 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $761.93M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $529.94M | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | $493.20M | Dec 1, 2025 |
| FY2024 | Sep 30, 2022 | $492.70M | Nov 29, 2024 |
| FY2023 | Sep 30, 2021 | $504.90M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $408.10M | Nov 29, 2022 |
| FY2021 | Sep 30, 2019 | $390.30M | Nov 29, 2021 |
| FY2020 | Sep 30, 2018 | $361.90M | Nov 30, 2020 |
| FY2019 | Mar 14, 2018 | $3.50M | Nov 29, 2019 |
| FY2019 | Sep 30, 2017 | $377.90M | Nov 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.37B | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $1.08B | Dec 1, 2025 |
| FY2024 | Sep 30, 2023 | $989.32M | Nov 29, 2024 |
| FY2023 | Sep 30, 2022 | $905.02M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $830.99M | Nov 29, 2022 |
| FY2021 | Sep 30, 2020 | $775.83M | Nov 29, 2021 |
| FY2020 | Sep 30, 2019 | $684.74M | Nov 30, 2020 |
| FY2019 | Sep 30, 2018 | $606.84M | Nov 29, 2019 |
| FY2018 | Sep 30, 2017 | $516.72M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $471.27M | Nov 29, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $101.35M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $65.96M | Dec 1, 2025 |
| FY2024 | Sep 30, 2023 | $41.87M | Nov 29, 2024 |
| FY2023 | Sep 30, 2022 | $97.72M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $56.23M | Nov 29, 2022 |
| FY2021 | Sep 30, 2020 | $52.56M | Nov 29, 2021 |
| FY2020 | Sep 30, 2019 | $61.81M | Nov 30, 2020 |
| FY2019 | Sep 30, 2018 | $30.48M | Nov 29, 2019 |
| FY2018 | Sep 30, 2017 | $45.52M | Nov 29, 2018 |
| FY2018 | Sep 30, 2016 | $53.83M | Nov 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $186.00M | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | $122.00M | Dec 1, 2025 |
| FY2024 | Sep 30, 2023 | $102.00M | Nov 29, 2024 |
| FY2023 | Sep 30, 2022 | $153.00M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $154.00M | Nov 29, 2022 |
| FY2021 | Sep 30, 2020 | $62.37M | Nov 29, 2021 |
| FY2020 | Sep 30, 2019 | $285.00M | Nov 30, 2020 |
| FY2019 | Sep 30, 2018 | $220.00M | Nov 29, 2019 |
| FY2018 | Sep 30, 2017 | $275.00M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $110.00M | Nov 29, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 11 | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | 3 | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | 3 | Dec 1, 2025 |
| FY2024 | Sep 30, 2022 | 3 | Nov 29, 2024 |
| FY2023 | Sep 30, 2021 | 2 | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Nov 30, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Nov 30, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Nov 30, 2020 |
| FY2020 | Dec 31, 2019 | 3 | Nov 30, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 30, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 11 | Dec 1, 2025 |
| FY2025 | Sep 30, 2024 | 3 | Dec 1, 2025 |
| FY2025 | Sep 30, 2023 | 3 | Dec 1, 2025 |
| FY2024 | Sep 30, 2022 | 3 | Nov 29, 2024 |
| FY2023 | Sep 30, 2021 | 2 | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Nov 30, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Nov 30, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Nov 30, 2020 |
| FY2020 | Dec 31, 2019 | 3 | Nov 30, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 30, 2020 |